References


63 Disp最重要的内容是关于新诊断的多发性骨髓瘤（Multiple Myeloma）的治疗。这些研究包括了不同类型的治疗方案，如高剂量化疗、自体干细胞移植等。研究还涉及了多种药物，如硼替佐米（Bortezomib）、达雷佐米（Daratumumab）等。这些药物在治疗新诊断的多发性骨髓瘤时显示出良好的疗效。研究还讨论了这些方案在不同人口群体中的应用，以及不同治疗方案的比较。
transplants in patients with multiple myeloma. Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second auto‐multiple myeloma. is superior to thalidomide–dexamethasone as consolidation therapy after autolo-
sone in patients with autografted myeloma. 121: 113–120.

Barlogie B, Attal M, Crowley J. et al. Long-term follow-up of autotransplantation
trials for multiple myeloma: update of protocols conducted by the Intergroup
Francophone du Myélome, Southwest Oncology Group, and University of

Morgan GI, Gregory WM, Davies FE, et al. The role of maintenance therapy for
multiple myeloma: MRC Myeloma IX results and meta-analysis. 113: 17–18.

Lokhorst H, van der Holt B, Zweegman S, et al. Final analysis of HOVON-50 ran-
domized phase III study on the effect of thalidomide combined with adriamycin,
dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple

effect of thalidomide combined with adriamycin, dexamethasone, and high-
dose melphalan, followed by thalidomide maintenance in patients with multiple
myeloma. 110: 1113–1120.

thalidomide and lenalidomide prolongs the survival of multiple myeloma patients

Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance ther-
apy in multiple myeloma. 119: 3083–3015.

Attal M, Laurent-Puig P, Cancer V, Marit G, et al. Lenalidomide maintenance after stem-

McCarthy PL, Oezar K, Hofmester CC, et al. Lenalidomide after stem-cell trans-

induction improves outcome of patients with (6/4) myeloma but not outcome of
patients with del(7p). 118: 4630–4634.

Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and
after autologous stem cell transplantation improves outcome in multiple myeloma
patients with high-risk disease. 120: 1770–1781.


Roussel L, Cibetra M, Mateos MV, et al. A phase III PHEMA/GEM random-
ized trial of posttransplant (ASCT) maintenance in multiple myeloma: superi-
ority of bortezomib/thalidomide compared with thalidomide and alfa2b interferon.

Roussel L, Cibetra M, Mateos MV, et al. A phase III PHEMA/GEM study of induc-

administration of bortezomib in patients with relapsed multiple myeloma: a ran-

Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bort-
zelomic in multiple myeloma patients. 2010; 116: 4745–4753.

Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecu-
lar remissions after consolidation with bortezomib, thalidomide, and dexametha-

consolidation after high dose melphalan: first results of a Nordic Myeloma Study

is superior to thalidomide–dexamethasone as consolidation therapy after auto-
logous hematopoietic stem cell transplantation in patients with newly diagnosed

Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second auto-

Jimenez-Rzapeta VH, Mikhad I, Winter A, et al. Second autologous stem cell
transplantation as salvage therapy for multiple myeloma: impact on progression-